FLX Bio, Inc., a South San Francisco, CA-based biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, raised $50m in Series B funding.
Backers included The Column Group (TCG), Topspin Partners, Kleiner Perkins Caufield & Byers (KPCB) and Celgene.
The company, which has raised a total of $79m, intends to use the funds to develop its pipeline of novel immuno-oncology compounds and its Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia.
Founded in 2015 by Brian Wong, M.D., PhD., President and Chief Executive Officer, FLX Bio is a biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents leveraging insights in cancer biology and the immune system. Originated from the acquisition of its predecessor company Flexus Biosciences by Bristol-Myers Squibb, FLX has assembled a management and leadership team with a proven track record of success and with substantial knowledge and expertise in the tumor microenvironment, drug discovery and translational areas essential to execute on this approach.